News Flash: 9 Analysts Think Mesoblast Limited (ASX:MSB) Earnings Are Under Threat, page-209

I missed this one at the time:

"On track to be a behemoth".

This opinion brought to you by the unimpeachable source behind:

- Risk in MSB is "baked out"
- Silviu's relationship with the FDA will see MSB right
- Magic catheters will see MSB right
- Boneheaded number crunchers nixed the deal of the century
- CHF sales by 2017
- DNA being stripped from cells
- MSB's cells are higher up the treatment chain
- Dilution doesn't matter if you don't have too many shares on issue

Yet still the naked attempts at ramping continue unabated.


I didn't manage to follow the argy bargy of the past few days in detail, but based on what I did see in passing, I believe that you can add the following to your list:

- Confessions of a boiler room operator is proof of shorters manipulating in order to accumulate shares.

.